Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year survival rate
of less than 8%, and is predicted to become the second leading cause of cancer-related …

Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …

Nerves are a component of the tumor microenvironment contributing to cancer progression,
but the role of cells from nerves in facilitating cancer invasion remains poorly understood …

Pancreatic ductal adenocarcinoma (PDA) is the most lethal of common human
malignancies, with no truly effective therapies for advanced disease. Preclinical studies …

One key feature of pancreatic ductal adenocarcinoma (PDAC) is a dense desmoplastic
reaction that has been recognized as playing important roles in metastasis and therapeutic …

A major barrier to successful pancreatic cancer (PC) treatment is the surrounding stroma,
which secretes growth factors/cytokines that promote PC progression. Wnt and tenascin C …

Pancreatic ductal adenocarcinoma is a devastating disease, and patient outcomes have not
improved in decades. Treatments that target tumor cells have largely failed. This could be …

Pancreatic ductal adenocarcinoma is characterized by an extensive stromal response called
desmoplasia. Within the tumor stroma, cancer-associated fibroblasts (CAFs) are the primary …

The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery:
What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract …

Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant
stroma in which microenvironmental (niche) factors promote PDAC progression. In mouse …